O	0	4	Long
O	4	5	-
O	5	9	term
O	10	16	safety
O	17	20	and
O	21	29	survival
O	30	38	outcomes
O	39	43	from
O	44	47	the
O	48	60	Scandinavian
O	61	67	Breast
O	68	73	Group
O	74	78	2004
O	78	79	-
O	79	80	1
O	81	91	randomized
O	92	97	phase
O	98	100	II
O	101	106	trial
O	107	109	of
B-intervention	110	118	tailored
I-intervention	119	123	dose
I-intervention	123	124	-
I-intervention	124	129	dense
I-intervention	130	138	adjuvant
I-intervention	139	151	chemotherapy
O	152	155	for
O	156	161	early
O	162	168	breast
O	169	175	cancer
O	175	176	.

O	177	185	Although
O	186	194	adjuvant
O	195	211	polychemotherapy
O	212	220	improves
O	221	229	outcomes
O	230	233	for
O	234	239	early
O	240	246	breast
O	247	253	cancer
O	253	254	,
O	255	258	the
O	259	270	significant
O	271	282	variability
O	283	285	in
O	286	291	terms
O	292	294	of
O	295	311	pharmacokinetics
O	312	319	results
O	320	322	in
O	323	334	differences
O	335	337	in
O	338	346	efficacy
O	347	350	and
O	351	355	both
O	356	361	short
O	362	365	and
O	366	370	long
O	370	371	-
O	371	375	term
O	376	386	toxicities
O	386	387	.

O	388	401	Retrospective
O	402	409	studies
O	410	417	support
O	418	421	the
O	422	425	use
O	426	428	of
O	429	433	dose
O	434	443	tailoring
O	444	453	according
O	454	456	to
O	457	460	the
O	461	472	hematologic
O	473	479	nadirs
O	479	480	.

O	481	484	The
O	485	488	SBG
O	489	493	2004
O	493	494	-
O	494	495	1
O	496	501	trial
O	502	505	was
O	506	507	a
O	508	518	randomized
O	519	530	feasibility
O	531	536	phase
O	537	539	II
O	540	545	study
O	546	551	which
O	552	560	assessed
O	561	569	tailored
O	570	574	dose
O	574	575	-
O	575	580	dense
O	581	591	epirubicin
O	592	595	and
O	596	612	cyclophosphamide
O	613	614	(
O	614	616	EC
O	616	617	)
O	618	626	followed
O	627	629	by
O	630	639	docetaxel
O	640	641	(
O	641	642	T
O	642	643	)
O	644	645	(
O	645	650	group
O	651	652	A
O	652	653	)
O	653	654	,
O	655	658	the
O	659	663	same
O	664	671	regimen
O	672	676	with
O	677	682	fixed
O	683	688	doses
O	689	690	(
O	690	695	group
O	696	697	B
O	697	698	)
O	699	702	and
O	703	706	the
B-control	707	710	TAC
I-control	711	718	regimen
O	719	720	(
O	720	725	group
O	726	727	C
O	727	728	)
O	728	729	.

O	730	735	Women
O	736	740	aged
B-age	741	743	18
I-age	743	744	-
I-age	744	746	65
I-age	747	752	years
O	752	753	,
B-eligibility	754	758	ECOG
I-eligibility	759	761	PS
I-eligibility	762	763	0
I-eligibility	763	764	-
I-eligibility	764	765	1
I-eligibility	766	770	with
I-eligibility	771	773	at
I-eligibility	774	779	least
I-eligibility	780	783	one
I-eligibility	784	792	positive
I-eligibility	793	801	axillary
I-eligibility	802	807	lymph
I-eligibility	808	812	node
O	813	817	were
O	818	828	randomized
O	829	830	1
O	830	831	:
O	831	832	1
O	832	833	:
O	833	834	1
O	834	835	.

O	836	839	The
O	840	847	primary
O	848	856	endpoint
O	857	859	of
O	860	863	the
O	864	869	study
O	870	873	was
O	874	877	the
B-outcome-Measure	878	884	safety
I-outcome-Measure	885	888	and
I-outcome-Measure	889	900	feasibility
I-outcome-Measure	901	903	of
I-outcome-Measure	904	907	the
I-outcome-Measure	908	917	treatment
O	917	918	.

O	919	927	Toxicity
O	928	931	was
O	932	938	graded
O	939	948	according
O	949	951	to
O	952	955	CTC
O	955	956	-
O	956	958	AE
O	959	966	version
O	967	968	3
O	968	969	.
O	969	970	0
O	970	971	.

O	972	975	The
O	976	982	design
O	983	986	and
O	987	992	short
O	992	993	-
O	993	997	term
O	998	1006	toxicity
O	1007	1011	have
O	1012	1016	been
O	1017	1027	previously
O	1028	1037	published
O	1037	1038	.

O	1039	1043	Here
O	1043	1044	,
O	1045	1047	we
O	1048	1054	report
O	1055	1061	safety
O	1062	1065	and
O	1066	1074	efficacy
O	1075	1079	data
O	1080	1085	after
O	1086	1088	10
O	1089	1094	years
O	1095	1097	of
O	1098	1104	follow
O	1104	1105	-
O	1105	1107	up
O	1107	1108	.

O	1109	1110	A
O	1111	1116	total
O	1117	1119	of
B-total-participants	1120	1123	124
O	1124	1132	patients
O	1133	1137	were
O	1138	1146	included
O	1147	1149	in
O	1150	1153	the
O	1154	1159	study
O	1159	1160	.

O	1161	1166	After
O	1167	1168	a
O	1169	1175	median
O	1176	1182	follow
O	1182	1183	-
O	1183	1185	up
O	1186	1188	of
O	1189	1191	10
O	1191	1192	.
O	1192	1193	3
O	1194	1199	years
O	1199	1200	,
O	1201	1204	the
B-outcome	1205	1216	probability
I-outcome	1217	1220	for
I-outcome	1221	1223	10
I-outcome	1223	1224	-
I-outcome	1224	1228	year
I-outcome	1229	1237	survival
O	1238	1241	was
B-iv-bin-percent	1242	1244	78
I-iv-bin-percent	1244	1245	.
I-iv-bin-percent	1245	1246	5
O	1246	1247	,
B-iv-bin-percent	1248	1250	75
I-iv-bin-percent	1250	1251	.
I-iv-bin-percent	1251	1252	1
O	1252	1253	,
O	1254	1257	and
B-cv-bin-percent	1258	1260	63
I-cv-bin-percent	1260	1261	.
I-cv-bin-percent	1261	1262	4
I-cv-bin-percent	1262	1263	%
O	1264	1267	and
O	1268	1271	for
B-outcome	1272	1279	relapse
I-outcome	1280	1284	free
I-outcome	1285	1293	survival
B-iv-bin-percent	1294	1296	64
I-iv-bin-percent	1296	1297	.
I-iv-bin-percent	1297	1298	1
O	1298	1299	,
B-iv-bin-percent	1300	1302	71
I-iv-bin-percent	1302	1303	.
I-iv-bin-percent	1303	1304	0
O	1304	1305	,
O	1306	1309	and
B-cv-bin-percent	1310	1312	59
I-cv-bin-percent	1312	1313	.
I-cv-bin-percent	1313	1314	5
I-cv-bin-percent	1314	1315	%
O	1316	1319	for
O	1320	1326	groups
O	1327	1328	A
O	1328	1329	,
O	1330	1331	B
O	1331	1332	,
O	1333	1336	and
O	1337	1338	C
O	1338	1339	,
O	1340	1352	respectively
O	1352	1353	.

O	1354	1359	There
O	1360	1364	were
O	1365	1367	no
O	1368	1373	cases
O	1374	1376	of
O	1377	1387	clinically
O	1388	1397	diagnosed
B-outcome	1398	1412	cardiotoxicity
I-outcome	1413	1415	or
I-outcome	1416	1427	hematologic
I-outcome	1428	1440	malignancies
O	1440	1441	.

O	1442	1444	No
O	1445	1452	patient
O	1453	1456	was
B-outcome	1457	1461	lost
I-outcome	1462	1464	to
I-outcome	1465	1471	follow
I-outcome	1471	1472	-
I-outcome	1472	1474	up
O	1474	1475	.

O	1476	1478	In
O	1479	1483	this
O	1484	1494	randomized
O	1495	1500	phase
O	1501	1503	II
O	1504	1509	trial
O	1509	1510	,
O	1511	1519	tailored
O	1520	1524	dose
O	1525	1533	adjuvant
O	1534	1546	chemotherapy
O	1547	1550	was
O	1551	1559	feasible
O	1559	1560	,
O	1561	1568	without
O	1569	1571	an
O	1572	1581	increased
O	1582	1586	risk
O	1587	1590	for
O	1591	1595	long
O	1595	1596	-
O	1596	1600	term
O	1601	1608	adverse
O	1609	1615	events
O	1616	1621	after
O	1622	1623	a
O	1624	1630	median
O	1631	1637	follow
O	1637	1638	-
O	1638	1640	up
O	1641	1643	of
O	1644	1646	10
O	1647	1652	years
O	1652	1653	.
